Opinion
Video
Author(s):
Paul Jeffrey, PharmD, presents the findings of a study, which investigated patient engagement and clinical outcomes associated with the use of prescription digital therapeutics (PDTs) in the treatment of substance use disorders, and discusses the need for further research to advance the efficacy and value of PDTs in this field.
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.